Skip to content

Study · Non-randomized trial · n = 50 · 1993

11 results

A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia.

Eri LM, Tveter KJ

The Journal of urology1 Aug 1993Cited by 34 (Europe PMC)

PMID7686981 (opens in a new tab)DOI10.1016/s0022-5347(17)35483-6 (opens in a new tab)PepBankPUB-07686981
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, prostate volume decreased by 34.5% with leuprolide and by 2.6% in the placebo group.

    In plain wordsIn patients with benign prostate enlargement, prostate volume decreased 34.5% with leuprolide and 2.6% with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseProstate volume
    Study

    n = 50

    Comparator
    Placebo group
    Outcome group
    Prostate volume · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Prostate volume decrease
    34.5%
    leuprolide
    Prostate volume decrease
    2.6%
    placebo group

    Source sentences

    Summary
    Prostate volume decreased by 34.5% (2.6% in the placebo group).
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, leuprolide improved maximum spontaneous urinary flow more than placebo.

    In plain wordsIn patients with benign prostate enlargement, leuprolide improved spontaneous urinary flow more than placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseMaximum spontaneous urinary flow
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Additional flow improvement
    2 ml. per second
    spontaneous micturition
    Additional flow improvement
    32%
    spontaneous micturition

    Source sentences

    Summary
    Maximum flow rate at spontaneous micturition and after instillation of saline improved by 2.0 ml. per second (32%) and 3.0 ml. per second (54%) more than with placebo.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, leuprolide improved maximum urinary flow after saline instillation more than placebo.

    In plain wordsIn patients with benign prostate enlargement, leuprolide improved urinary flow after saline instillation more than placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseMaximum flow after saline instillation
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Additional flow improvement
    3 ml. per second
    after saline
    Additional flow improvement
    54%
    after saline

    Source sentences

    Summary
    Maximum flow rate at spontaneous micturition and after instillation of saline improved by 2.0 ml. per second (32%) and 3.0 ml. per second (54%) more than with placebo.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, leuprolide reduced detrusor pressure during micturition by approximately 24% compared with placebo.

    In plain wordsIn patients with benign prostate enlargement, bladder pressure during urination decreased with leuprolide compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseDetrusor pressure
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Detrusor pressure decrease
    ≈ 24%
    versus placebo

    Source sentences

    Summary
    Detrusor pressure during micturition decreased by approximately 24% for patients who received leuprolide compared to placebo and was accompanied by a 25% increase in flow rate, which indicated decreased bladder outlet resistance.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, the leuprolide-associated pressure decrease accompanied a 25% increase in urinary flow compared with placebo.

    In plain wordsIn patients with benign prostate enlargement, urinary flow increased with leuprolide compared with placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseUrinary flow accompanying pressure decrease
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Flow increase
    25%
    leuprolide

    Source sentences

    Summary
    Detrusor pressure during micturition decreased by approximately 24% for patients who received leuprolide compared to placebo and was accompanied by a 25% increase in flow rate, which indicated decreased bladder outlet resistance.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, irritative symptoms improved significantly more with leuprolide than placebo at week 48.

    In plain wordsIn patients with benign prostate enlargement, leuprolide improved irritative symptoms more than placebo at week 48.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedIrritative symptoms at week 48
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    At between group comparison, the improvement for irritative symptoms in favor of leuprolide reached statistical significance at week 48.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  7. 07HumanNon-randomized trialMechanism

    In patients with benign prostatic hyperplasia, pressure and flow changes indicated decreased bladder outlet resistance with leuprolide compared with placebo.

    In plain wordsIn patients with benign prostate enlargement, pressure and flow changes indicated less bladder outlet resistance with leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseBladder outlet resistance
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Detrusor pressure during micturition decreased by approximately 24% for patients who received leuprolide compared to placebo and was accompanied by a 25% increase in flow rate, which indicated decreased bladder outlet resistance.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with benign prostatic hyperplasia, symptom scores improved significantly from baseline in both groups, including leuprolide and placebo.

    In plain wordsIn patients with benign prostate enlargement, symptom scores improved from baseline in both the leuprolide and placebo groups.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedSymptom scores during treatment
    Study

    n = 50

    Comparator
    Pretreatment
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Symptom scores improved significantly for both groups throughout the study when compared to those before treatment.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  9. 09HumanNon-randomized trialSafety outcome

    In patients with benign prostatic hyperplasia, leuprolide was well tolerated with few exceptions despite side effects.

    In plain wordsIn patients with benign prostate enlargement, leuprolide was generally well tolerated despite side effects.

    Peptide
    Leuprolide
    Outcome
    Not applicableTreatment tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    With few exceptions, leuprolide patients tolerated the treatment well even if they had side effects, such as flushing and decreased sexual function.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  10. 10HumanNon-randomized trialSafety outcome

    Patients with benign prostatic hyperplasia receiving leuprolide reported flushing.

    In plain wordsPatients with benign prostate enlargement reported flushing during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Not applicableFlushing
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    With few exceptions, leuprolide patients tolerated the treatment well even if they had side effects, such as flushing and decreased sexual function.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.
  11. 11HumanNon-randomized trialSafety outcome

    Patients with benign prostatic hyperplasia receiving leuprolide reported decreased sexual function.

    In plain wordsPatients with benign prostate enlargement reported reduced sexual function during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseDecreased sexual function
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · injection every 28 days · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    With few exceptions, leuprolide patients tolerated the treatment well even if they had side effects, such as flushing and decreased sexual function.
    1 context sentence
    Summary · context
    We investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.